STRATEGIC STUDIES IN RADIOPHARMACEUTICALS: AN OVERVIEW OF BRAZILIAN AND GLOBAL HEALTH TECHNOLOGIES IN ONCOLOGICAL THERAPY

Radiopharmaceuticals are essential for the diagnosis and treatment of cancer, but their supply has been a long-standing problem in Brazil. Constitutional Amendment No. 118 (2022), which ended the state monopoly on the production of medical radioisotopes, opened a new scenario for this market. This study aimed to evaluate the Brazilian and global overview of radiopharmaceuticals used in oncology, in order to generate technological information for decision-making in the Brazilian Unified Health System (SUS). The methodology comprised three stages: (i) a search for radiopharmaceuticals with active registration in the database of the National Health Surveillance Agency (ANVISA), classified under ATC codes V09 and V10; (ii) a survey of radiotherapy-related procedures in the SUS, using DATASUS, SIGTAP and the Painel Oncologia Brasil; and (iii) a search of the Cortellis Drug Discovery Intelligence (CDDI) database, which retrieved 5,644 pharmaceuticals and biologicals. The results show a diverse set of registered products, with fludeoxyglucose 18F (18F-FDG) holding the largest number of registrations, by several companies, and describe the regulatory framework applicable to these products. Globally, few radiopharmaceuticals reach the market compared with the number in preclinical and clinical development; gallium (759 records) and technetium (536) were the elements most often found in complexes, and fluorine was the most frequent in radiolabeled products. The study provides initial strategic information for researchers, managers and decision-makers and may contribute to strengthening nuclear medicine in the SUS.

Authors

Institutions

Publication Details

Journal
Cadernos Cajuína
Published
2026-11-18
DOI
https://doi.org/10.52641/cadcajv11i17.155
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

STRATEGIC STUDIES IN RADIOPHARMACEUTICALS: AN OVERVIEW OF BRAZILIAN AND GLOBAL HEALTH TECHNOLOGIES IN ONCOLOGICAL THERAPY

Adelaide María de Souza Antunes, Jorge Lima de Magalhães, Rita de Cássia Pinheiro Machado, Alessandra Moreira de Oliveira
Cadernos Cajuína
Radiopharmaceutical Chemistry and Applications
article

STRATEGIC STUDIES IN RADIOPHARMACEUTICALS: AN OVERVIEW OF BRAZILIAN AND GLOBAL HEALTH TECHNOLOGIES IN ONCOLOGICAL THERAPY

Adelaide María de Souza Antunes, Jorge Lima de Magalhães, Rita de Cássia Pinheiro Machado, Alessandra Moreira de Oliveira
article en

Abstract

Radiopharmaceuticals are essential for the diagnosis and treatment of cancer, but their supply has been a long-standing problem in Brazil. Constitutional Amendment No. 118 (2022), which ended the state monopoly on the production of medical radioisotopes, opened a new scenario for this market. This study aimed to evaluate the Brazilian and global overview of radiopharmaceuticals used in oncology, in order to generate technological information for decision-making in the Brazilian Unified Health System (SUS). The methodology comprised three stages: (i) a search for radiopharmaceuticals with active registration in the database of the National Health Surveillance Agency (ANVISA), classified under ATC codes V09 and V10; (ii) a survey of radiotherapy-related procedures in the SUS, using DATASUS, SIGTAP and the Painel Oncologia Brasil; and (iii) a search of the Cortellis Drug Discovery Intelligence (CDDI) database, which retrieved 5,644 pharmaceuticals and biologicals. The results show a diverse set of registered products, with fludeoxyglucose 18F (18F-FDG) holding the largest number of registrations, by several companies, and describe the regulatory framework applicable to these products. Globally, few radiopharmaceuticals reach the market compared with the number in preclinical and clinical development; gallium (759 records) and technetium (536) were the elements most often found in complexes, and fluorine was the most frequent in radiolabeled products. The study provides initial strategic information for researchers, managers and decision-makers and may contribute to strengthening nuclear medicine in the SUS.

Cadernos CajuínaVol. 11(17)
Instituto Nacional da Propriedade Industrial (BR), Instituto Nacional da Propriedade Industrial (PT), Instituto de Tecnologia em Fármacos (BR), Fundação Oswaldo Cruz (BR)
Good health and well-being
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon